Bilinski and Boyages have previously reported that the frequency of vitamin D testing had risen dramatically in Australia between 2000 and 2010.1,2 Further, testing did not translate to improved health outcomes.3 Since that report,1 Medicare Benefits Schedule (MBS) expenditure on vitamin D testing rose from $109.0 million in the 2009–10 financial year to $151.1 million in 2012–13, falling slightly in 2013–14 to $143.1 million.
- 1. Bilinski KL, Boyages SC. The rising cost of vitamin D testing in Australia: time to establish guidelines for testing. Med J Aust 2012; 197: 90. <MJA full text>
- 2. Bilinski K, Boyages S. Evidence of overtesting for vitamin D in Australia: an analysis of 4.5 years of Medicare Benefits Schedule (MBS) data. BMJ Open 2013; 3: e002955. doi: 10.1136/bmjopen-2013-002955.
- 3. Australian Government Department of Health. MBS reviews: vitamin D testing report, February 2014. http://www.msac.gov.au/internet/msac/publishing.nsf/Content/932329F88F2367D3CA257D77008073B9/$File/Vitamin%20D%20testing%20Review%20Report-accessible.pdf (accessed Oct 2015).
- 4. Simpao AFA, Luis M, Galvez, et al. A review of analytics and clinical informatics in health care [review]. J Med Systems 2014; 38: 45.
- 5. Daly RM GC, Lu ZX, et al. Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol (Oxf) 2012; 77: 26-35.
- 6. Boyages S, Bilinski K. Seasonal reduction in vitamin D level persists into spring in NSW Australia: implications for monitoring and replacement therapy. Clin Endocrinol (Oxf) 2012; 77: 515-523.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.